Nektar Therapeutics (NASDAQ: NKTR) is one of the best hot stocks to buy according to Wall Street analysts. On June 24, Nektar ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Figure skater Michelle Hong used to hide her skin as much as possible due to her condition—but with effective treatment and ...

Nektar’s shares have surged more than twofold after a Phase IIb study of its atopic dermatitis (AD) therapy rezpegaldesleukin ...

Doctors report a steady increase in eczema cases among infants across Indian cities. Experts warn that genetics and ...

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

Biologic medications have emerged as game-changers for moderate to severe eczema cases. Dupixent and Adbry target specific immune system components responsible for the inflammatory cascade that ...